Press release content from Globe Newswire. The AP news staff was not involved in its creation.
argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China
Zai Lab Limited; argenxJanuary 6, 2021 GMT Collaboration to expand and accelerate global development of efgartigimod; expected to allow argenx to more rapidly advance new potential indications into clinical development each year Zai Lab granted exclusive rights to develop and commercialize efgartigimod in Greater China
argenx to receive $75 million in upfront Zai Lab equity and $100 million in near-term milestone and other payments
Regulated Information/Inside Information
BREDA, the Netherlands and SHANGHAI and SAN FRANCISCO, Jan. 06, 2021 (GLOBE NEWSWIRE) argenx SE (Euronext & NASDAQ: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage